Cingulate (CINGW) Receivables - Net (2023 - 2024)

Cingulate's (CINGW) quarterly Receivables - Net came in at $2247.0 in Q3 2024, down 99.86% quarter-over-quarter from $1.6 million in Q2 2024.

Analysis

Cingulate (CINGW) Receivables - Net (2023 - 2024) Analysis & Trends

Cingulate (CINGW) has reported Receivables - Net for 2 consecutive years, with $2247.0 the latest figure, recorded in Q3 2024.

For the quarter ending Q3 2024, Receivables - Net changed N/A year-over-year to $2247.0; the trailing twelve-month figure through Sep 2024 stood at $2247.0 (changed N/A YoY), and the FY2023 full-year result was $14622.0, changed N/A from the prior year.
Receivables - Net fell to $2247.0 in Q3 2024 per CINGW's latest filing, from $1.6 million in the prior quarter.
Across five years, Receivables - Net topped out at $1.6 million in Q2 2024 and bottomed at $2247.0 in Q3 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	644.46 Bn	623.70 Bn	17.26 Bn
2	AbbVie	440.11 Bn	433.54 Bn	12.70 Bn
3	Merck	365.04 Bn	357.90 Bn	12.21 Bn
4	Novartis Ag	266.82 Bn	259.13 Bn	11.24 Bn
5	Pfizer	159.14 Bn	147.45 Bn	10.94 Bn
6	Sanofi	52.47 Bn	45.09 Bn	10.79 Bn
7	Revolution Medicines	44.26 Bn	44.26 Bn	-
8	Incyte	25.32 Bn	20.79 Bn	1.57 Bn
9	United Therapeutics	21.46 Bn	18.80 Bn	683.80 Mn
10	Cingulate	100,214.03	100,214.03	-

Historic Data

Download Data